Drug Resistance UpdatesBMJ 2000; 321 doi: https://doi.org/10.1136/bmj.321.7271.1295 (Published 18 November 2000) Cite this as: BMJ 2000;321:1295
- Pentti Huovinen, chief physician
Churchill Livingstone, annual subscription £90, 6 issues a year
ISSN 1368 7646
Drug resistance of different cell types is an increasing medical problem, at least with regard to infectious diseases and oncology.
Drug Resistance Updates is a new review journal on the subject of antimicrobial and anticancer chemotherapy. The word “chemotherapy” has traditionally been used in these two fields, reflected in the names of congresses, like the International Congress of Chemotherapy, and journals, like the Journal of Antimicrobial Chemotherapy. But in clinical microbiology and infectious diseases, other words—antimicrobial, antibacterial, antiviral therapy—are increasingly used. The new journal has adopted these new divisions: cancer, bacteria, viruses, fungi, and protozoa are discussed in five different sections.
The editorial boards of all five sections are made up of leading professionals. This is usually a guarantee of high quality in the review process, and it also provides a great source of writers. The reviews in my own field, bacterial resistance, published in the four 1999 issues were written by highly respected authors.
Although I am usually resistant to new journals, Drug Resistance Updates was a delightful surprise. The biggest challenge to the editors will be to compete with the good quality reviews in biomedical journals with a high impact factor. I am eager to see whether this journal makes its mark. It deserves to be a success.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial